trending Market Intelligence /marketintelligence/en/news-insights/trending/I4EnUWvx_yqdFBI-X1Peig2 content esgSubNav
In This List

S&P affirms Amneal Pharmaceuticals' corporate credit rating after Impax deal

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet

Blog

Insight Weekly: Stocks limp into 2023; GCC banks set for rebound; deep-sea mining faces pushback

Infographic

Infographic: The Big Picture 2023 Sustainability Outlook

Blog

The Big Picture for 2023: Assessing Investment Trends and the Impact of Investor Activism


S&P affirms Amneal Pharmaceuticals' corporate credit rating after Impax deal

S&P Global Ratings affirmed its BB- corporate credit rating on Amneal Pharmaceuticals LLC after the company's decision to merge with Impax Laboratories Inc.

The outlook remains negative.

S&P said the affirmation reflects the rating agency's view that the deal improves Amneal Pharmaceuticals' scale and diversity by adding specialty drugs to its business.

The rating agency said the outlook remains negative because the deal delays deleveraging given Impax Laboratories' higher leverage and it believes a transaction of this size raises integration risk.

S&P said the negative outlook also reflects its view that the pricing environment for generic drugs will remain challenging and takes into account Amneal's history of underperforming S&P's cash flow projections.

S&P Global Ratings and S&P Global Market Intelligence are owned by S&P Global Inc.